Mariam Swidan: Hemolytic Anemia – Disease Overview
Mariam Swidan, Biomedical Science Graduate, Clinical Laboratory Professional, shared a post on LinkedIn:
“Hemolytic Anemia – Disease Overview
Definition
Hemolytic anemia is a condition characterized by premature destruction of red blood cells (RBCs), leading to a decreased RBC lifespan (less than 120 days) and insufficient compensation by the bone marrow.
Pathophysiology
- RBC destruction exceeds production
- Bone marrow responds – increased reticulocytes
- Hemoglobin breakdown – increased bilirubin
- Can occur intravascularly or extravascularly (spleen)
Classification
1. Intrinsic (RBC defect)
Usually hereditary
- Membrane defects (e.g., spherocytosis)
- Enzyme deficiencies (e.g., G6PD deficiency)
- Hemoglobinopathies (e.g., sickle cell disease, thalassemia)
2. Extrinsic (external factors)
Usually acquired
- Autoimmune hemolytic anemia
- Infections (e.g., malaria)
- Microangiopathic (DIC, TTP, HUS)
- Drugs/toxins
Clinical features
- Fatigue, pallor
- Jaundice (increased bilirubin)
- Dark urine (hemoglobinuria)
- Splenomegaly (especially extravascular)
Laboratory findings
Key pattern:
- Hb decreased
- Reticulocytes increased
- LDH increased
- Indirect bilirubin increased
- Haptoglobin decreased
Blood smear (depends on cause):
- Spherocytes
- Schistocytes
- Bite cells
Types of hemolysis
Intravascular
- RBC destruction in circulation
- Hemoglobinemia and hemoglobinuria
Extravascular
- RBC destruction in spleen/liver
- Increased splenomegaly, less hemoglobinuria
Management (depends on cause)
- Treat underlying condition
- Folic acid supplementation
- Immunosuppressants (if autoimmune)
- Splenectomy (selected cases)
- Blood transfusion if severe
The body tries to compensate for hemolysis by increasing RBC production – that’s why reticulocyte count is one of the most important markers in diagnosis.”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support